Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467711 | 1.00 | NPY5R (0.60) | NPY5RUSP30 | |
| SCHEMBL5467705 | 1.00 | NPY5R (0.60) | NPY5RUSP30 | |
| SCHEMBL5483738 | 1.00 | NPY5R (0.60) | NPY5RUSP30 | |
| SCHEMBL5471743 | 0.94 | NPY5R (0.58) | NPY5R | |
| SCHEMBL5471748 | 0.94 | NPY5R (0.58) | NPY5R | |
| SCHEMBL5475272 | 0.94 | NPY5R (0.62) | NPY5R | |
| SCHEMBL5482838 | 0.94 | NPY5R (0.62) | NPY5R | |
| SCHEMBL6848567 | 0.87 | NPY5R (0.56) | NPY5R | |
| SCHEMBL6848571 | 0.87 | NPY5R (0.56) | NPY5R | |
| SCHEMBL5471475 | 0.85 | NPY5R (0.52) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | NPY5R 83/4885USP30 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.